- Home
- VUZI vs TLSI Comparison
VUZI vs TLSI Comparison
Compare VUZI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VUZI
- TLSI
- Stock Information
- Founded
- VUZI 1997
- TLSI 2010
- Country
- VUZI United States
- TLSI United States
- Employees
- VUZI N/A
- TLSI N/A
- Industry
- VUZI Industrial Machinery/Components
- TLSI Medical Specialities
- Sector
- VUZI Technology
- TLSI Health Care
- Exchange
- VUZI Nasdaq
- TLSI Nasdaq
- Market Cap
- VUZI 236.4M
- TLSI 204.0M
- IPO Year
- VUZI N/A
- TLSI N/A
- Fundamental
- Price
- VUZI $2.95
- TLSI $5.19
- Analyst Decision
- VUZI Strong Buy
- TLSI Strong Buy
- Analyst Count
- VUZI 1
- TLSI 5
- Target Price
- VUZI $2.00
- TLSI $10.90
- AVG Volume (30 Days)
- VUZI 2.1M
- TLSI 42.1K
- Earning Date
- VUZI 05-12-2025
- TLSI 08-13-2025
- Dividend Yield
- VUZI N/A
- TLSI N/A
- EPS Growth
- VUZI N/A
- TLSI N/A
- EPS
- VUZI N/A
- TLSI N/A
- Revenue
- VUZI $5,331,630.00
- TLSI $32,141,000.00
- Revenue This Year
- VUZI $45.35
- TLSI $55.52
- Revenue Next Year
- VUZI $54.01
- TLSI $54.76
- P/E Ratio
- VUZI N/A
- TLSI N/A
- Revenue Growth
- VUZI N/A
- TLSI 46.20
- 52 Week Low
- VUZI $0.83
- TLSI $3.50
- 52 Week High
- VUZI $5.79
- TLSI $6.18
- Technical
- Relative Strength Index (RSI)
- VUZI 55.12
- TLSI 46.05
- Support Level
- VUZI $2.81
- TLSI $5.13
- Resistance Level
- VUZI $3.43
- TLSI $5.55
- Average True Range (ATR)
- VUZI 0.28
- TLSI 0.34
- MACD
- VUZI -0.01
- TLSI 0.00
- Stochastic Oscillator
- VUZI 47.83
- TLSI 31.94
About VUZI Vuzix Corporation
Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.